Sign in or Register   Sign in or Register
  |  

Mouse Anti-LAG3 Recombinant Antibody (CBYJL-1055) (CBMAB-L0482-YJ)

Provided herein is a Mouse monoclonal antibody, which binds to Lymphocyte Activating 3 (LAG3). The antibody can be used for immunoassay techniques, such as ELISA.
See all LAG3 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBYJL-1055
Antibody Isotype
IgG1
Application
ELISA

Basic Information

Immunogen
Human Lymphocyte Activation Gene 3.
Specificity
Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Buffer
PBS, pH 7.4
Storage
Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
lymphocyte activating 3
Introduction
Lymphocyte-activation protein 3 belongs to Ig superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. Pathways related to it are NF-kappaB Signaling and Innate Immune System. Gene Ontology (GO) annotations related to this gene include transmembrane signaling receptor activity and MHC class II protein binding.Lymphocyte Activating 3 is involved in lymphocyte activation.
Entrez Gene ID
UniProt ID
Function
Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells (PubMed:7805750, PubMed:8647185, PubMed:20421648).
Delivers inhibitory signals upon binding to ligands, such as FGL1 (By similarity).
FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function (By similarity).
Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity).
May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1 (By similarity).
Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells (PubMed:7805750, PubMed:8647185, PubMed:20421648).
Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity).
Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity).
Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear (PubMed:8647185).
Secreted lymphocyte activation gene 3 protein
May function as a ligand for MHC class II (MHC-II) on antigen-presenting cells (APC), promoting APC activation/maturation and driving Th1 immune response.
Biological Process
Adaptive immune responseIEA:UniProtKB-KW
Cell surface receptor signaling pathwayISS:UniProtKB
Negative regulation of interleukin-2 productionIEA:Ensembl
Negative regulation of regulatory T cell differentiationISS:UniProtKB
Plasmacytoid dendritic cell activationISS:UniProtKB
Positive regulation of natural killer cell mediated cytotoxicityIEA:Ensembl
Regulation of immune responseISS:UniProtKB
Cellular Location
Lymphocyte activation gene 3 protein:
Cell membrane
Secreted lymphocyte activation gene 3 protein:
Secreted
Produced following cleavage of the main chain.
Topology
Extracellular: 23-450
Helical: 451-471
Cytoplasmic: 472-525
PTM
Lymphocyte activation gene 3 protein
Proteolytically cleaved by ADAM10 and ADAM17 within the connecting peptide region, leading to release of Secreted lymphocyte activation gene 3 protein (sLAG-3). ADAM10 mediates constitutive cleavage, but cleavage increases following T-cell activation, whereas shedding by ADAM17 is induced by TCR signaling in a PRKCQ-dependent manner.

Zhao, L., Wang, H., Xu, K., Liu, X., & He, Y. (2022). Update on lymphocyte-activation gene 3 (LAG-3) in cancers: From biological properties to clinical applications. Chinese Medical Journal, 135(10), 1203-1212.

Lythgoe, M. P., Liu, D. S. K., Annels, N. E., Krell, J., & Frampton, A. E. (2021). Gene of the month: Lymphocyte-activation gene 3 (LAG-3). Journal of Clinical Pathology, 74(9), 543-547.

Slevin, S. M., Garner, L. C., Lahiff, C., Tan, M., Wang, L. M., Ferry, H., ... & Keshav, S. (2020). Lymphocyte activation gene (LAG)-3 is associated with mucosal inflammation and disease activity in ulcerative colitis. Journal of Crohn's and Colitis, 14(10), 1446-1461.

Gebauer, F., Krämer, M., Bruns, C., Schlößer, H. A., Thelen, M., Lohneis, P., ... & Quaas, A. (2020). Lymphocyte activation gene-3 (LAG3) mRNA and protein expression on tumour infiltrating lymphocytes (TILs) in oesophageal adenocarcinoma. Journal of cancer research and clinical oncology, 146, 2319-2327.

Atkinson, V., Khattak, A., Haydon, A., Eastgate, M., Roy, A., Prithviraj, P., ... & Triebel, F. (2020). Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. Journal for immunotherapy of cancer, 8(2).

Yu, X., Huang, X., Chen, X., Liu, J., Wu, C., Pu, Q., ... & Zhou, L. (2019, August). Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy. In MAbs (Vol. 11, No. 6, pp. 1139-1148). Taylor & Francis.

Ruffo, E., Wu, R. C., Bruno, T. C., Workman, C. J., & Vignali, D. A. (2019, April). Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. In Seminars in immunology (Vol. 42, p. 101305). Academic Press.

Saleh, R. R., Peinado, P., Fuentes-Antrás, J., Pérez-Segura, P., Pandiella, A., Amir, E., & Ocaña, A. (2019). Prognostic value of lymphocyte-activation gene 3 (LAG3) in cancer: a meta-analysis. Frontiers in oncology, 9, 1040.

Zhang, Y., Liu, Y. D., Luo, Y. L., Liu, B. L., Huang, Q. T., Wang, F., & Zhong, Q. (2018). Prognostic value of lymphocyte activation gene-3 (LAG-3) expression in esophageal squamous cell carcinoma. Journal of Cancer, 9(22), 4287.

Wang, Y., Dong, T., Xuan, Q., Zhao, H., Qin, L., & Zhang, Q. (2018). Lymphocyte-activation gene-3 expression and prognostic value in neoadjuvant-treated triple-negative breast cancer. Journal of breast cancer, 21(2), 124-133.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-LAG3 Recombinant Antibody (CBYJL-1055)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare